Skip to content
urologyjournal
Search for:
Search for:
Home
Uncategorized
Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST
By
urologyjournal
Posted on
February 1, 2024
Posted in
Uncategorized
Post navigation
Scroll to top